Ontology highlight
ABSTRACT: Background
Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.Patients and methods
We carried out droplet digital polymerase chain reaction to detect BRAF and NRAS mutations in plasma taken after surgery from 161 stage II/III high-risk melanoma patients enrolled in the AVAST-M adjuvant trial.Results
Mutant BRAF or NRAS ctDNA was detected (?1 copy of mutant ctDNA) in 15/132 (11%) BRAF mutant patient samples and 4/29 (14%) NRAS mutant patient samples. Patients with detectable ctDNA had a decreased disease-free interval [DFI; hazard ratio (HR) 3.12; 95% confidence interval (CI) 1.79-5.47; P?ConclusionctDNA predicts for relapse and survival in high-risk resected melanoma and could aid selection of patients for adjuvant therapy.Clinical trial number
ISRCTN 81261306.
SUBMITTER: Lee RJ
PROVIDER: S-EPMC5834029 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Lee R J RJ Gremel G G Marshall A A Myers K A KA Fisher N N Dunn J A JA Dhomen N N Corrie P G PG Middleton M R MR Lorigan P P Marais R R
Annals of oncology : official journal of the European Society for Medical Oncology 20180201 2
<h4>Background</h4>Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.<h4>Patients and methods</h4>We carried out droplet digital polymerase chain reaction to detect BRAF and NRAS mutations in plasma taken after surgery from 161 stage II/I ...[more]